The current standard of care for surgically eligible stage I non-small cell lung cancer (NSCLC) is surgical resection, but emerging data suggest that stereotactic body radiation therapy (SBRT) is potentially as effective as surgery.
Among the 237 children not on ART at the time of the study, 13%% were eligible (stage 3 or 4, or severely immunodeficient).
Combining the results for HCA2 and HC10 staining resulted in 1,008 eligible stage I IV rectal cancer patients for analyses of clinical impact of HLA class I expression.
Medically inoperable patients with an FDG PET-positive lesion in the lung without FDG uptake elsewhere were eligible (stage I lung cancer, according to the UICC TNM Classification of Malignant Tumours, 7th edition, 2009).
To reflect disease progression, we assumed that all HIV-infected people progress from primary/acute HIV infection, to chronic/asymptomatic infection, to a treatment-eligible stage, and then may receive treatment (Fig. 1).
According to our model, after 10 years of universal access to ART without second-line options ∼20% of treatment-naïve cases in asymptomatic stage would have some drug-resistant strains and ∼17% of cases at treatment-eligible stage of infection would have some drug-resistant strains (Fig. 2b, c).
The sampling procedure was a multi-stage (three-level) cluster sampling aimed at selecting eligible persons: Stage 1, selection of enumeration areas within the LGA; Stage 2, enlistment of eligible individuals within households; Stage 3, selection of respondents for interview and examination.
Among 536 patients (response rate of 82.8%) completed the baseline survey, condition-specific Functional Assessment of Cancer Therapy-Colorectal (FACT-C) and generic SF-12 and SF-6D Health Survey were administered to 160 eligible patients (Stage III: 115, 71.9%; Stage IV: 45, 28.1%) by a trained research assistant after written consent was obtained.
A Simon two-stage phase-II clinical trial design enrolling a minimum of 35 (stage-1) and a maximum of 60 eligible patients (stage-2) was chosen to get at least 25% of GSTP1-AA patients with a difference in terms of PFS greater that 1.5-fold with respect to genotypes harbouring any G-allele.
At 3 weeks after surgery, eligible pathological stage II IV (M0) cases were randomly assigned at a 1 : 1 ratio to receive the Mf or MFP regimen.
